Cargando…

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

SU5416 (Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone; semaxanib) is a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR)2. A Phase I dose escalation study was performed. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used as a pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Donnell, A, Padhani, A, Hayes, C, Kakkar, A J, Leach, M, Trigo, J M, Scurr, M, Raynaud, F, Phillips, S, Aherne, W, Hardcastle, A, Workman, P, Hannah, A, Judson, I
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361651/ https://www.ncbi.nlm.nih.gov/pubmed/16222321 http://dx.doi.org/10.1038/sj.bjc.6602797

Ejemplares similares

A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies
por: Benepal, T, et al.
Publicado: (2005)

The aryl hydrocarbon receptor is required for induction of p21(cip1/waf1) expression and growth inhibition by SU5416 in hepatoma cells
por: O’Donnell, Edmond F., et al.
Publicado: (2017)

SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model
por: Peloquin, Grace L., et al.
Publicado: (2019)

SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation
por: Mezrich, Joshua D., et al.
Publicado: (2012)

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)
por: Beale, P, et al.
Publicado: (2003)

Human Mesenchymal Stem Cell Therapy Reverses Su5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
por: Alencar, Allan K. N., et al.
Publicado: (2018)

Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours
por: Harries, M, et al.
Publicado: (2004)

Effects of the vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor SU5416 on in vitro cultures of Plasmodium falciparum
por: Hempel, Casper, et al.
Publicado: (2014)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
por: Sanada, Takayuki J., et al.
Publicado: (2020)

Vascular Endothelial Growth Factor Receptor Inhibitor SU5416 Suppresses Lymphocyte Generation and Immune Responses in Mice by Increasing Plasma Corticosterone
por: Grailer, Jamison J., et al.
Publicado: (2013)

Upregulation of Aquaporin 1 Mediates Increased Migration and Proliferation in Pulmonary Vascular Cells From the Rat SU5416/Hypoxia Model of Pulmonary Hypertension
por: Yun, Xin, et al.
Publicado: (2021)

SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration
por: Thill, Michelle, et al.
Publicado: (2011)

SU5416 attenuated lipopolysaccharide-induced acute lung injury in mice by modulating properties of vascular endothelial cells
por: Huang, Xuqing, et al.
Publicado: (2019)

Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition
por: Yu, Min, et al.
Publicado: (2020)

The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats
por: Shoji, Hiroki, et al.
Publicado: (2021)

Normalization of the Lymph Node T Cell Stromal Microenvironment in lpr/lpr Mice Is Associated with SU5416-Induced Reduction in Autoantibodies
por: Chyou, Susan, et al.
Publicado: (2012)

Natural reversal of pulmonary vascular remodeling and right ventricular remodeling in SU5416/hypoxia-treated Sprague-Dawley rats
por: Zungu-Edmondson, Makhosazane, et al.
Publicado: (2017)

Partially hydrolyzed guar gum suppresses the progression of pulmonary arterial hypertension in a SU5416/hypoxia rat model
por: Sanada, Takayuki J., et al.
Publicado: (2023)

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification
por: DePrimo, Samuel E, et al.
Publicado: (2003)

Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells
por: Liu, Ping, et al.
Publicado: (2021)

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
por: Benson, C, et al.
Publicado: (2007)

Unexpected Neuronal Protection of SU5416 against 1-Methyl-4-Phenylpyridinium Ion-Induced Toxicity via Inhibiting Neuronal Nitric Oxide Synthase
por: Cui, Wei, et al.
Publicado: (2012)

Hormonal impact of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
por: O'Donnell, A, et al.
Publicado: (2004)

Effects of SU5416 and a vascular endothelial growth factor neutralizing antibody on wear debris-induced inflammatory osteolysis in a mouse model
por: Ren, Weiping, et al.
Publicado: (2011)

Echocardiographic evaluation of right heart failure which might be associated with DNA damage response in SU5416-hypoxia induced pulmonary hypertension rat model
por: Kuang, Meidan, et al.
Publicado: (2023)

SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling
por: Sitapara, Ravikumar, et al.
Publicado: (2021)

Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
por: Yu, Tian, et al.
Publicado: (2016)

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
por: O’Donnell, John P, et al.
Publicado: (2023)

The selective PGI(2) receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats
por: Honda, Yohei, et al.
Publicado: (2020)

Response to: Are endothelial cell proliferation and mesenchymal transition as distinguishing characteristics of 3-week Sugen5416/hypoxia mice model?
por: Rodor, Julie, et al.
Publicado: (2023)

Human Umbilical Cord-Derived Mesenchymal Stem Cells Repair SU5416-Injured Emphysema by Inhibiting Apoptosis via Rescuing VEGF-VEGFR2-AKT Pathway in Rats
por: Chen, Qin, et al.
Publicado: (2022)

A patient presenting with a perivascular epithelioid cell tumor in the broad ligament: a case report
por: Ross, Claire, et al.
Publicado: (2011)

Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
por: Findlay, M. P., et al.
Publicado: (1997)

Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitorD9331
por: Webley, S D, et al.
Publicado: (2000)

Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?
por: Schoots, Ivo G., et al.
Publicado: (2019)

A phase I study of the nitroimidazole hypoxia marker SR4554 using (19)F magnetic resonance spectroscopy
por: Lee, C P, et al.
Publicado: (2009)

1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury
por: Avedissian, Sean N, et al.
Publicado: (2019)

Improvement of the antimicrobial potency, pharmacokinetic and pharmacodynamic properties of albicidin by incorporation of nitrogen atoms
por: Zborovsky, Lieby, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1mdmrtunajfini12lqceetrbtf